SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Radius Health, Inc. MergerNewsfile Corp • 06/24/22
Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square CapitalBusiness Wire • 06/24/22
Shareholder Alert: Ademi LLP investigates whether Radius Health, Inc. has obtained a Fair Price in its transaction with Gurnet Point and Patient SquarePRNewsWire • 06/23/22
RDUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Radius Health, Inc. Is Fair to ShareholdersBusiness Wire • 06/23/22
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square CapitalGlobeNewsWire • 06/23/22
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for ElacestrantPRNewsWire • 06/22/22
Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to StockholdersBusiness Wire • 06/21/22
Velan-Repertoire Responds to Misleading Characterizations by the Radius BoardBusiness Wire • 06/13/22
Velan-Repertoire Group Files Definitive Proxy Materials in Connection With Radius Health 2022 Annual MeetingBusiness Wire • 06/07/22
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 06/06/22
Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast CancerBenzinga • 05/20/22
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of DirectorsGlobeNewsWire • 05/20/22
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical OncologyPRNewsWire • 05/20/22
Radius Health, Inc. (RDUS) CEO Kelly Martin on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22